Q1 2018 Earnings Forecast for InVitae Corp (NVTA) Issued By William Blair

InVitae Corp (NYSE:NVTA) – Research analysts at William Blair reduced their Q1 2018 earnings per share (EPS) estimates for InVitae in a report issued on Tuesday. William Blair analyst A. Murphy now anticipates that the medical research company will post earnings per share of ($0.59) for the quarter, down from their previous estimate of ($0.54). William Blair also issued estimates for InVitae’s Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.47) EPS, Q4 2018 earnings at ($0.41) EPS, FY2018 earnings at ($2.00) EPS, Q1 2019 earnings at ($0.37) EPS, Q2 2019 earnings at ($0.33) EPS, Q3 2019 earnings at ($0.29) EPS, Q4 2019 earnings at ($0.23) EPS and FY2019 earnings at ($1.22) EPS.

InVitae (NYSE:NVTA) last announced its quarterly earnings data on Monday, February 12th. The medical research company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.17). InVitae had a negative return on equity of 134.68% and a negative net margin of 180.85%. The firm had revenue of $25.40 million during the quarter, compared to analysts’ expectations of $24.18 million. During the same quarter in the previous year, the business earned ($0.69) earnings per share. The company’s revenue for the quarter was up 175.0% compared to the same quarter last year.

Several other analysts have also commented on the company. JPMorgan Chase & Co. dropped their target price on InVitae from $13.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday. Benchmark dropped their target price on InVitae from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. ValuEngine lowered InVitae from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Leerink Swann dropped their target price on InVitae from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services assumed coverage on InVitae in a report on Friday, January 5th. They set a “buy” rating and a $15.00 target price on the stock. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. InVitae has a consensus rating of “Hold” and an average price target of $11.00.

InVitae (NVTA) opened at $6.16 on Thursday. InVitae has a 12 month low of $3.80 and a 12 month high of $10.41. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.61 and a current ratio of 2.61.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Lakeview Capital Partners LLC acquired a new stake in shares of InVitae in the third quarter worth approximately $117,000. Teacher Retirement System of Texas acquired a new stake in shares of InVitae in the fourth quarter worth approximately $116,000. Gabelli Funds LLC acquired a new stake in shares of InVitae in the third quarter worth approximately $131,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of InVitae in the third quarter worth approximately $133,000. Finally, Granite Springs Asset Management LLC acquired a new stake in shares of InVitae in the fourth quarter worth approximately $132,000. 65.12% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/15/q1-2018-earnings-forecast-for-invitae-corp-nvta-issued-by-william-blair.html.

About InVitae

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Earnings History and Estimates for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply